A Retrospective Analysis of the Dose-intensity and Toxicities of Accelerated Versus Standard-schedule Chemotherapy for Early Breast Cancer in a Real-world Setting
Purpose: The 10-year mortality benefit of dose-dense over standard-schedule chemotherapy in early breast cancer was established in an EBCTCG meta-analysis published this year [1]. We sought to compare dose-intensity and toxicities in a real-world setting.
Source: Clinical Oncology - Category: Radiology Authors: J.D. Towler, K. Ball, Z. Hu, P. Riddle Source Type: research